Antiplatelet therapy. Is it working?

- At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological effect\(^{1,2,3}\)
- 40% of patients receiving clopidogrel (Plavix\(^{®}\)) may not adequately respond to therapy\(^4\)
- Hyper-response is associated with an increased risk of bleeding\(^5\)
- Individual response to antiplatelet therapies can change over time\(^6\)

Thus, understanding a patient’s unique response to antiplatelet medications is essential for effective medical decision-making.

VerifyNow testing offers antiplatelet therapy guidance in many clinical scenarios

- Interventional procedures for endovascular aneurysm treatment
- Cardiovascular surgery requiring patients to suspend antiplatelet therapy
- Surgery involving patients taking antiplatelet therapy who are at risk for bleeding

For better patient management

One of the most cited and utilized platelet reactivity testing systems, VerifyNow is an indispensable aid to understanding the complete patient profile. Monitoring patient response to antiplatelet medication optimizes patient outcomes.

**VerifyNow testing:**

- Offers platelet reactivity results in minutes
- Measures the effect of antiplatelet therapies prior to a procedure or discharge
- Identifies patients at risk for an antiplatelet-related bleeding or thrombotic event
- Identifies therapeutic noncompliance

**VerifyNow testing may help:**

- Reduce time off antiplatelet therapy and its associated risks
- Reduce the need for standard pre-op platelet orders
- Optimize patient length of stay prior to surgery
- Reduce 30-day readmissions
Variability in antiplatelet response

Factors contributing to variations in patient response to antiplatelet medication include:

- Concomitant medications
- Genetic differences
- Current health conditions
- Patient noncompliance

Variability in antiplatelet response

Challenge

Patients with inadequate response to antiplatelet medications may be at significantly greater risk of myocardial infarction and stent thrombosis.

A number of commonly prescribed antiplatelet medications block the P2Y12 platelet-receptor, reducing the risk of major adverse cardiac events (MACE).

VerifyNow PRUTest™

Measures the level of platelet P2Y12 platelet-receptor blockade to help identify patient response to antiplatelet therapy.

VerifyNow Aspirin Test

Aids in assessing how aspirin inhibits platelets, allowing rapid, informed treatment decisions.

Challenge

Whether used alone or as part of a dual antiplatelet therapy, not all patients respond to aspirin equally.

Up to 30% of patients demonstrate lower-than-expected levels of platelet inhibition while on aspirin therapy, putting them at greater risk of heart attack, stroke and other vascular events. Alternatively, other patients can exhibit a hyper-response, increasing bleeding risk.
Simple integration into any workflow

- Easy to use
- No pipetting or sample preparation
- Sample-to-answer results in a fully contained, single-use test system

Uses Light Transmission Aggregometry (LTA)-correlated technology

- Requires no sample manipulation, eliminating analytical sample variation
- Patented, accurate and intuitive
- Gold standard technology for pharmaceutical drug development
Specific drug-receptor site activation

**VerifyNow PRUTest**
Uses ADP and PGE1 to measure the degree of P2Y12 platelet-receptor blockade, identifying patient response to a P2Y12 inhibitor.

**VerifyNow Aspirin Test**
Utilizes an arachidonic acid-initiated reaction to measure platelet response to aspirin.

Commonly prescribed antiplatelet medications, including clopidogrel (Plavix®), prasugrel (Effient®) and ticagrelor (Brilinta®/Brilique), block the platelet P2Y12 receptor.

---

**VerifyNow testing supports patient care in many areas of the hospital**

- Cardiac Care Unit
- Interventional Neuroradiology Suite
- Emergency Department
- Cardiac Catheterization Laboratory
- Laboratory
Customer testimonials

“Testing with VerifyNow supports ongoing expansion of the frontiers of endovascular aneurysm treatment by helping minimize risk of perioperative complications.”
Josser E. Delgado, MD
Neurointerventionalist
Abbott Northwestern Hospital
Neuroscience Institute
Minneapolis, Minnesota

“I test all patients on platelet inhibitors prior to open heart surgery to assess whether or not antiplatelet therapies are having their desired effect.”
Pierre R. Tibi, MD
Cardiothoracic Surgeon and Medical Director
The James Family Heart Center at YRMC
West Prescott, Arizona

“Having the VerifyNow system allows me to assess the effect of the chosen antiplatelet treatment strategies and make informed decisions.”
J. Brent Muhlestein, MD
Interventional Cardiologist
Intermountain Heart Institute
Murray, Utah

References

Distributed in Australia & New Zealand by

www.haemoview.com.au
E: info@haemoview.com.au